JP2022519196A5 - - Google Patents
Info
- Publication number
- JP2022519196A5 JP2022519196A5 JP2021542516A JP2021542516A JP2022519196A5 JP 2022519196 A5 JP2022519196 A5 JP 2022519196A5 JP 2021542516 A JP2021542516 A JP 2021542516A JP 2021542516 A JP2021542516 A JP 2021542516A JP 2022519196 A5 JP2022519196 A5 JP 2022519196A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- effective amount
- treated
- chemotherapy
- tpo mimetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796728P | 2019-01-25 | 2019-01-25 | |
| US62/796,728 | 2019-01-25 | ||
| PCT/US2020/015015 WO2020154637A1 (en) | 2019-01-25 | 2020-01-24 | Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519196A JP2022519196A (ja) | 2022-03-22 |
| JP2022519196A5 true JP2022519196A5 (enExample) | 2023-02-02 |
| JP7664163B2 JP7664163B2 (ja) | 2025-04-17 |
Family
ID=69740564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542516A Active JP7664163B2 (ja) | 2019-01-25 | 2020-01-24 | 全身照射／化学曝露に対する応答において臓器および血管損傷、造血回復ならびに生存に対する保護を増強する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200237872A1 (enExample) |
| EP (1) | EP3914281A1 (enExample) |
| JP (1) | JP7664163B2 (enExample) |
| KR (1) | KR20210119469A (enExample) |
| CN (1) | CN113660943A (enExample) |
| AU (1) | AU2020210869A1 (enExample) |
| CA (1) | CA3127458A1 (enExample) |
| IL (1) | IL285092A (enExample) |
| MA (1) | MA54821A (enExample) |
| MX (1) | MX2021008928A (enExample) |
| WO (1) | WO2020154637A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7481252B2 (ja) | 2017-07-26 | 2024-05-10 | ヤンセン ファーマシューティカ エヌ．ベー． | 標的放射線治療誘発性血管完全性を保護する方法 |
| MA54820A (fr) * | 2019-01-25 | 2021-12-01 | Janssen Pharmaceutica Nv | Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques |
| CN118660955A (zh) * | 2021-10-01 | 2024-09-17 | 詹森药业有限公司 | 增加祖细胞生产的方法 |
| WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680422B2 (en) | 1992-06-11 | 1997-07-31 | Alkermes Controlled Therapeutics, Inc. | Erythropoietin drug delivery system |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US7091311B2 (en) | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| RS20060141A (sr) | 2003-08-28 | 2008-08-07 | Ortho-Mcneil Pharmaceutical Inc., | Peptidi i jedinjenja koja se vežu za receptor |
| US7723295B2 (en) | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
| US20060210542A1 (en) | 2004-08-16 | 2006-09-21 | Yurkow Edward J | Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia |
| US7615533B2 (en) | 2004-08-16 | 2009-11-10 | Janssen Pharmaceutica N.V. | TPO peptide compounds for treatment of anemia |
| PT1984014E (pt) | 2006-02-14 | 2014-11-13 | Janssen Pharmaceutica Nv | Utilização de compostos de péptidos tpo e composições farmacêuticas no tratamento da anemia |
| KR20110015448A (ko) | 2008-06-03 | 2011-02-15 | 얀센 파마슈티카 엔.브이. | 암 치료와 관련된 혈액 질환을 예방하기 위한 ｔｐｏ 모방 펩티드 |
| BR112014028094B1 (pt) * | 2012-05-09 | 2022-03-03 | Cantex Pharmaceuticals, Inc | Uso de um heparinoide interagindo com fator de plaqueta 4 |
| US20140051631A1 (en) * | 2012-08-17 | 2014-02-20 | Francoise Porteu | Pharmaceutical composition comprising tpo or an agonist of the tpo receptor |
| JP6150374B2 (ja) * | 2012-11-15 | 2017-06-21 | 国立大学法人弘前大学 | 放射線被ばく治療剤及び放射線被ばく治療方法 |
-
2020
- 2020-01-24 US US16/752,559 patent/US20200237872A1/en not_active Abandoned
- 2020-01-24 CA CA3127458A patent/CA3127458A1/en active Pending
- 2020-01-24 WO PCT/US2020/015015 patent/WO2020154637A1/en not_active Ceased
- 2020-01-24 AU AU2020210869A patent/AU2020210869A1/en not_active Abandoned
- 2020-01-24 JP JP2021542516A patent/JP7664163B2/ja active Active
- 2020-01-24 EP EP20708763.6A patent/EP3914281A1/en not_active Withdrawn
- 2020-01-24 MX MX2021008928A patent/MX2021008928A/es unknown
- 2020-01-24 MA MA054821A patent/MA54821A/fr unknown
- 2020-01-24 KR KR1020217026699A patent/KR20210119469A/ko not_active Ceased
- 2020-01-24 CN CN202080023563.6A patent/CN113660943A/zh active Pending
-
2021
- 2021-07-23 IL IL285092A patent/IL285092A/en unknown
-
2022
- 2022-02-18 US US17/651,675 patent/US20220168392A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502117A5 (enExample) | ||
| AU2001230977A1 (en) | Combinations for treating neoplasms | |
| Kolb et al. | The FLAMSA concept—past and future | |
| Mastrangelo et al. | Position paper: Role of 131I‐metaiodobenzylguanidine in the treatment of neuroblastoma | |
| RU2335539C2 (ru) | Фармацевтический препарат и способ лечения злокачественных опухолей у человека с помощью аргининовой депривации | |
| JP7245548B2 (ja) | 造血幹細胞移植患者の処置 | |
| McAfee et al. | Dose-escalated total body irradiation and autologous stem cell transplantation for refractory hematologic malignancy | |
| Cieza‐Díaz et al. | Romidepsin in combination with low‐dose methotrexate in advanced‐stage mycosis fungoides and Sézary syndrome. | |
| EP4366721A1 (en) | Melflufen for use in the treatment of multiple myeloma | |
| EP2089401B1 (en) | Use of tri-substituted glycerol compounds for the treatment of radiation injuries | |
| Miura et al. | An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma | |
| Zwick et al. | Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma | |
| JP2842888B2 (ja) | リボヌクレアーゼインヒビターを有効成分とする癌細胞転移抑制剤 | |
| CN112533605A (zh) | 用于治疗癌症的组合疗法 | |
| US20250375458A1 (en) | Compositions and methods to combat multidrug-resistant and persistent t-cell-mediated, oncological and infectious diseases | |
| JP2009091348A (ja) | がんの治療方法 | |
| Zorina et al. | PROSPECTS FOR THE USE OF ALPHA-2-MACROGLOBULIN AS A RADIOPROTECTIVE AGENT | |
| Kovacs et al. | Altered radioprotective properties of interleukin Iα (IL-1) in non-hematologic tumor-bearing animals | |
| Boesen | Mannitol busulphan in disseminated breast carcinoma | |
| Gorelik et al. | ROLE OF NATURAL-CELL-MEDIATED IMMUNITY IN URETHAN-INDUCED LUNG CARCINOGENESIS | |
| Becker et al. | Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer | |
| CN117940119A (zh) | 美氟芬用于多发性骨髓瘤的治疗 | |
| Tilgen et al. | Current therapy strategies for malignant melanoma with special regard to immunotherapy with cytokines | |
| Werner-Wasik | Clinical applications of radioprotectors | |
| HK40040825A (zh) | 用於治疗癌症的组合疗法 |